Insulin and IGF-I stimulate normal and virally transformed T-lymphocyte cell growth in vitro. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Insulin and IGF-I stimulate normal and virally transformed T-lymphocyte cell growth in vitro.

Brain Behav Immun. 1992 Dec;6(4):377-86. Unique Identifier : AIDSLINE MED/93144828
Geffner ME; Bersch N; Golde DW; Department of Pediatrics, UCLA School of Medicine 90024.


Abstract: We used normal and HTLV-II-transformed T-lymphocytes as target cells to study clonal proliferative responses to physiologic and supraphysiologic concentrations of insulin and IGF-I. Responses of both growth factors were measured in the presence and absence of alpha IR-3, and IGF-I receptor-blocking antibody. A biphasic response to insulin was noted in all cell lines with the first peak [78 +/- 6.6% (mean +/- SE) above control] occurring at 1.4 or 1.6 nmol/liter and a second peak (84 +/- 4.9% above control) occurring at 18.0 nmol/liter. Following preincubation with alpha IR-3, the overall clonal profile in response to insulin was significantly reduced [F(7,56) = (10.4, p < .0001] as a result of blunting at high physiologic and supraphysiologic insulin concentrations, i.e., > or = 1.6 nmol/liter. As expected, the overall clonal profile in response to IGF-I was blocked by alpha IR-3 [F(4,32) = 11.6, p < .0001]. These data show that insulin at both physiologic and supraphysiologic concentrations, as well as IGF-I, stimulate virally transformed T-lymphoblast growth. The significant inhibition of growth responses to high concentrations of insulin and to IGF-I by alpha IR-3 suggests mediation of these effects through the IGF-I receptor. Similar studies were performed using freshly isolated, phytohemagglutinin (PHA)-stimulated T-lymphocytes. The overall response to insulin was significantly reduced compared to the profile of transformed T-lymphoblasts [F(7,70) = 4.9, p = .0002] as a result of blunting at physiologic insulin concentrations < 1.8 nmol/liter. In response to IGF-I, the clonal profile of PHA-stimulated T-lymphocytes was slightly reduced compared to that of virally transformed T-lymphoblasts [F(4,40) = 3.4, p = .0174]. Thus, both insulin and IGF-I receptor-effector mechanisms are involved in the growth of virally transformed T-lymphoblasts, whereas the IGF-I receptor-effector mechanism appears to play a more significant role in the growth of normal, mitogen-activated T-lymphocytes.
Keywords: Cell Division/DRUG EFFECTS Cell Line, Transformed *Cell Transformation, Viral Cells, Cultured Clone Cells/DRUG EFFECTS Human HTLV-II/*PHYSIOLOGY Insulin/*PHARMACOLOGY Insulin-Like Growth Factor I/*PHARMACOLOGY Receptors, Insulin-Like-Growth Factor I/ANTAGONISTS & INHIB Stimulation, Chemical Support, U.S. Gov't, P.H.S. T-Lymphocytes/*DRUG EFFECTS JOURNAL ARTICLEKWDcelldivision/drugeffectscellline,transformedKWDcelltransformation,viralcells,culturedclonecells/drugeffectshumanhtlv-ii/KWDphysiologyinsulin/KWDpharmacologyinsulin-likegrowthfactori/KWDpharmacologyreceptors,insulin-like-growthfactori/antagonists&inhibstimulation,chemicalsupport,uKWDsKWDgov't,pKWDhKWDsKWDt-lymphocytes/KWDdrugeffectsjournalarticle
930530
M9350951

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .